The content on this site is intended for healthcare professionals only
Dr Julie Gralow comments on the phase 3 DETERMINATION trial using Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM).
The primary outcome was that Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance prolongs disease control and improves survival for newly diagnosed multiple myeloma patients.
Dr Gralow concludes the by discussing the significance of the study findings.
Watch Dr Richardson's interview on the study here
Watch Dr Richardson's press conference on the study here
Read the news article here
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Synthetic biology and precision medicine in blood and gynaecological cancers
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC
Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC
Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection
